A Case of Encapsulating Peritoneal Sclerosis in a Patient Receiving Peritoneal Dialysis and Glucocorticoid Therapy

Encapsulating peritoneal sclerosis (EPS) is a fatal complication of peritoneal dialysis. A 68-year-old man undergoing PD for 10 years started receiving daily 50 mg of glucocorticoids for idiopathic pulmonary sclerosis. At the transition to hemodialysis, a peritoneal biopsy was performed, which demon...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2023, pp.1760-23
Main Authors: Taguch, Kensei, Mitsuishi, Yuta, Ito, Sakuya, Moriyama, Tomofumi, Fukami, Kei
Format: Article
Language:English
Subjects:
duodenal stenosis
encapsulating peritoneal sclerosis
end-stage renal disease
peritoneal dialysis
prednisone
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Encapsulating peritoneal sclerosis (EPS) is a fatal complication of peritoneal dialysis. A 68-year-old man undergoing PD for 10 years started receiving daily 50 mg of glucocorticoids for idiopathic pulmonary sclerosis. At the transition to hemodialysis, a peritoneal biopsy was performed, which demonstrated mild histological changes, including no fibrin formation and mild T lymphocyte infiltration at the time of 6.5 mg glucocorticoids. However, five months later, he developed EPS when receiving 2.5 mg glucocorticoids. Afterward, over 5 mg daily glucocorticoids were required to avoid the recurrence of EPS. These findings suggest that glucocorticoids may conceal peritoneal inflammation, a main contributor to EPS.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.1760-23